Loading
New York breast oncologist and cancer geneticist who led OlympiAD, the trial that made olaparib the first PARP inhibitor approved for BRCA-mutated breast cancer.
Mark Robson leads the breast medicine service at Memorial Sloan Kettering Cancer Center and works at the interface of clinical genetics and breast oncology. He was first author of the 2017 New England Journal of Medicine report of OlympiAD, which showed that olaparib improved progression-free survival compared with standard chemotherapy in HER2-negative metastatic breast cancer with a germline BRCA mutation, the first PARP inhibitor approval in breast cancer.
| Title | Journal | Year |
|---|---|---|
| OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation | New England Journal of Medicine | 2017 |
Sets the surgical and systemic rules for the one in nine to one in six triple-negative patients who carry a germline BRCA variant (11 to 17 percent by cohort); the adjuvant gap it named was filled by OlympiA the following year.
Germline BRCA testing became part of metastatic breast cancer work-up, and olaparib (with talazoparib after EMBRACA) is a standard option, especially for triple-negative disease.
Shares Breast cancer (all types) and the tags breast, trialist.
Shares the tags breast, trialist.
Shares the tags breast, trialist.
Shares Breast cancer (all types) and the tags breast, trialist.
Shares Breast cancer (all types) and the tags breast, trialist.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tags breast, trialist.
Shares Breast cancer (all types) and the tags breast, trialist.
Shares the tags breast, trialist.